Drugs

, Volume 71, Issue 5, pp 541–555 | Cite as

Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer

  • Branislav Bystricky
  • Alicia F. C. Okines
  • David Cunningham
Review Article

Abstract

Oesophageal cancer is the eighth most common cancer diagnosed worldwide, with almost half a million new cases diagnosed each year. Despite improvements in surgical and radiotherapy techniques and refinements of chemotherapeutic regimens, long-term survival, even from localized oesophageal cancer, remains poor.

Surgical resection alone remains the standard approach for very early stage disease (stage I), but whilst surgery remains fundamental to the treatment of stage II–III resectable adenocarcinoma, multimodality therapy with chemotherapy or chemoradiation (CRT) is internationally accepted as the standard of care. Data from two large, randomized phase III trials support the use of perioperative combination chemotherapy in lower oesophageal and oesophagogastric junction adenocarcinomas, but the contribution of the adjuvant therapy is uncertain. There are conflicting data from randomized studies of a purely neoadjuvant approach; however, recent meta-analyses have demonstrated that chemotherapy or CRT given prior to radical surgery improves survival in patients with adenocarcinoma of the oesophagus.

Neoadjuvant CRT but not chemotherapy alone is also beneficial for patients with squamous cell carcinoma. Definitive CRT has emerged as a useful option for the treatment of resectable squamous cell carcinoma of the oesophagus, avoiding potential surgical morbidity and mortality for most patients, with salvage surgery reserved for those with persistent disease.

In this review, we focus on the pharmacotherapy of resectable oesophageal and oesophagogastric junction cancers and how clinical trials and meta-analyses inform current clinical practice.

Notes

Acknowledgements

Branislav Bystricky has no relevant conflicts of interest. Alicia Okines previously received an honorarium and travel support for a presentation from Roche (May 2008). David Cunningham has received research funding from Amgen, Merck and Roche.

Branislav Bystricky, Alicia Okines and David Cunningham acknowledge National Health Service funding to the National Institute for Health Research (NIHR) Biomedical Research Centre.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC CancerBase no. 10. Lyon, France: International Agency for Research on Cancer; 2010 [online]. Available from URL: http://globocan.iarc.fr [Accessed 2010 Nov 3]
  2. 2.
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. Epub 2010 Jun 17Google Scholar
  3. 3.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24(14): 2137–50PubMedCrossRefGoogle Scholar
  4. 4.
    CancerResearchUK. Oesophageal cancer — UK mortality statistics, 2010 [online]. Available from URL: http://info.cancerresearchuk.org/cancerstats/types/oesophagus/survival/ [Accessed 2010 Nov 3]
  5. 5.
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85(11): 1457–9PubMedCrossRefGoogle Scholar
  6. 6.
    Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell, 2009Google Scholar
  7. 7.
    Altekruse S, Kosary CL, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2007. Bethesda (MD): National Cancer Institute. Based on November 2009 SEER data submission, posted to the SEER web site, 2010 [online]. Available from ULR: http://seer.cancer.gov/csr/1975_2007/ [Accessed 2010 Nov 3]
  8. 8.
    Ajani J. NCCN practice guidelines in oncology — esophageal cancer v 2. 2011 Jan 31]Google Scholar
  9. 9.
    Lerut T, Coosemans W, De Leyn P, et al. Is there a role for radical esophagectomy? Eur J Cardiothoracic Surg 1999; 16 Suppl. 1: S44–7CrossRefGoogle Scholar
  10. 10.
    Allum WH, Griffin SM, Watson A, et al.; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; British Society of Gastroenterology; British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50 Suppl. 5: v1–23PubMedCrossRefGoogle Scholar
  11. 11.
    Mariette C, Seitz JF, Maillard E, et al. Impact of neoadjuvant chemoradiation in localized esophageal cancer: results of a randomized, controlled phase III trial. FFCD 9901 [abstract no. 800O]. 35th ESMO Congress; 2010 Oct 8–12; MilanGoogle Scholar
  12. 12.
    Chiu PW, Chan AC, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005; 9(6): 794–802PubMedCrossRefGoogle Scholar
  13. 13.
    Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15(6): 947–54PubMedCrossRefGoogle Scholar
  14. 14.
    Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326(24): 1593–8PubMedCrossRefGoogle Scholar
  15. 15.
    Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281(17): 1623–7Google Scholar
  16. 16.
    Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; (1): CD002092Google Scholar
  17. 17.
    Sykes AJ, Burt PA, Slevin NJ, et al. Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery. Radiother Oncol 1998; 48(1): 15–21PubMedCrossRefGoogle Scholar
  18. 18.
    Amdal CD, Jacobsen AB, Tausjø JE, et al. Radical treatment for oesophageal cancer patients unfit for surgery and chemotherapy: a 10-year experience from the Norwegian Radium Hospital. Acta Oncol 2010; 49(2): 209–18PubMedCrossRefGoogle Scholar
  19. 19.
    Wang Y, Shi XH, He SQ, et al. Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 2002; 54(1): 131–6PubMedCrossRefGoogle Scholar
  20. 20.
    Zhao KL, Shi XH, Jiang GL, et al. Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma. Int J Radiat Oncol Biol Phys 2004; 60(1): 123–9PubMedCrossRefGoogle Scholar
  21. 21.
    Arnott SJ, Duncan W, Gignoux M, et al.; Oeosphageal Cancer Collaborative Group. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; (4): CD001799Google Scholar
  22. 22.
    Schlag P. Randomized study of preoperative chemotherapy in squamous cell cancer of the esophagus: CAO Esophageal Cancer Study Group [in German]. Chirurg 1992; 63(9): 709–14PubMedGoogle Scholar
  23. 23.
    Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16(6): 1104–9; discussion 1110Google Scholar
  24. 24.
    Maipang T, Vasinanukorn P, Petpichetchian C, et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994; 56(3): 191–7PubMedCrossRefGoogle Scholar
  25. 25.
    Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114(2): 210–7PubMedCrossRefGoogle Scholar
  26. 26.
    Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91(11): 2165–74PubMedCrossRefGoogle Scholar
  27. 27.
    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359(9319): 1727–33CrossRefGoogle Scholar
  28. 28.
    Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27(30): 5062–7PubMedCrossRefGoogle Scholar
  29. 29.
    Kelsen DP, Winter KA, Gunderson LL, et al.; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25(24): 3719–25PubMedCrossRefGoogle Scholar
  30. 30.
    Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339(27): 1979–84PubMedCrossRefGoogle Scholar
  31. 31.
    Cunningham D, Allum WH, Stenning SP, et al.; MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1): 11–20PubMedCrossRefGoogle Scholar
  32. 32.
    Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial [abstract]. J Clin Oncol 2007; 25 (18S June 20 Suppl.): 4510Google Scholar
  33. 33.
    Gebski V, Burmeister B, Smithers BM, et al.; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8(3): 226–34PubMedCrossRefGoogle Scholar
  34. 34.
    Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41(4): 391–3PubMedGoogle Scholar
  35. 35.
    Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337(3): 161–7PubMedCrossRefGoogle Scholar
  36. 36.
    Natsugoe S, Okumura H, Matsumoto M, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus 2006; 19(6): 468–72PubMedCrossRefGoogle Scholar
  37. 37.
    Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26(7): 1086–92PubMedCrossRefGoogle Scholar
  38. 38.
    Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19(2): 305–13PubMedGoogle Scholar
  39. 39.
    Burmeister BH, Smithers BM, Gebski V, et al.; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6(9): 659–68PubMedCrossRefGoogle Scholar
  40. 40.
    Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20(5): 1167–74PubMedCrossRefGoogle Scholar
  41. 41.
    Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23(10): 2310–7PubMedCrossRefGoogle Scholar
  42. 42.
    Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25(10): 1160–8PubMedCrossRefGoogle Scholar
  43. 43.
    Borghesi S, Hawkins MA, Tait D. Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol) 2008; 20(3): 221–6CrossRefGoogle Scholar
  44. 44.
    Wales Cancer Trials Unit. Cisplatin, capecitabine, and radiation therapy with or without cetuximab in treating patients with esophageal cancer [clinicalTrials.gov identifier NCT00509561]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 2]Google Scholar
  45. 45.
    Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114(2): 205–9PubMedCrossRefGoogle Scholar
  46. 46.
    Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study — JCOG 9204. J Clin Oncol 2003; 21(24): 4592–6PubMedCrossRefGoogle Scholar
  47. 47.
    Ténière P, Hay JM, Fingerhut A, et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial: French University Association for Surgical Research. Surg Gynecol Obstet 1991; 173(2): 123–30PubMedGoogle Scholar
  48. 48.
    Fok M, Sham JS, Choy D, et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 113(2): 138–47PubMedGoogle Scholar
  49. 49.
    Zieren HU, Müller JM, Jacobi CA, et al. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 1995; 19(3): 444–9PubMedCrossRefGoogle Scholar
  50. 50.
    Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 2003; 75(2): 331–6PubMedCrossRefGoogle Scholar
  51. 51.
    Malthaner RA, Wong RK, Rumble RB, et al.; Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35PubMedCrossRefGoogle Scholar
  52. 52.
    Tachibana M, Yoshimura H, Kinugasa S, et al. Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. Eur J Surg Oncol 2003; 29(7): 580–7PubMedCrossRefGoogle Scholar
  53. 53.
    Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347(21): 1662–9PubMedCrossRefGoogle Scholar
  54. 54.
    Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246(6): 992–1000; discussion 1000-1PubMedCrossRefGoogle Scholar
  55. 55.
    Chang AC, Ji H, Birkmeyer NJ, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008; 85(2): 424–9PubMedCrossRefGoogle Scholar
  56. 56.
    Biere SS, Cuesta MA, van der Peet DL. Minimally invasive versus open esophagectomy for cancer: a systematic review and meta-analysis. Minerva Chir 2009; 64(2): 121–33PubMedGoogle Scholar
  57. 57.
    Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 2006; 202(4): 588–96; discussion 596-8PubMedCrossRefGoogle Scholar
  58. 58.
    Lerut T, Nafteux P, Moons J, et al. Three-field lympha-denectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240(6): 962–72; discussion 972-4PubMedCrossRefGoogle Scholar
  59. 59.
    Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002; 236(3): 376–84; discussion 384-5PubMedCrossRefGoogle Scholar
  60. 60.
    Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008) [abstract no. 4515]. Int J Clin Oncol 2009; 27 Suppl.: 15sGoogle Scholar
  61. 61.
    Medical Research Council Combination chemotherapy in treating patients with esophageal cancer [ClinicalTrials.gov identifier NCT00041262]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 2]
  62. 62.
    Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [published erratum appears in N Engl J Med 1999 Jul 29; 341 (5): 384]. N Engl J Med 1996; 335(7): 462–7PubMedCrossRefGoogle Scholar
  63. 63.
    Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27(6): 851–6PubMedCrossRefGoogle Scholar
  64. 64.
    Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24(29): 4692–8PubMedCrossRefGoogle Scholar
  65. 65.
    Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8(9): 797–805PubMedCrossRefGoogle Scholar
  66. 66.
    Lordick F, Meyer Zum Bueschenfelde C, Herrmann K, et al. PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): the MUNICON-II study. 2011 Gastrointestinal Cancers Symposium [abstract]. J Clin Oncol 2011; 29 Suppl. 4: 3Google Scholar
  67. 67.
    Bamias A, Cunningham D, Nicolson V, et al. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study. Br J Cancer 1995; 71(3): 583–6PubMedCrossRefGoogle Scholar
  68. 68.
    Armanios M, Xu R, Forastiere AA, et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group [published erratum appears in J Clin Oncol 2008 Aug 1; 26 (22): 3819]. J Clin Oncol 2004; 22(22): 4495–9PubMedCrossRefGoogle Scholar
  69. 69.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345(10): 725–30PubMedCrossRefGoogle Scholar
  70. 70.
    Cunningham D, Starling N, Rao S, et al.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1): 36–46PubMedCrossRefGoogle Scholar
  71. 71.
    Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20(9): 1529–34PubMedCrossRefGoogle Scholar
  72. 72.
    Bang YJ, Van Cutsem E, Feyereislova A, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published erratum appears in Lancet 2010 Oct 16; 376 (9749): 1302]. Lancet 2010; 376(9742): 687–97PubMedCrossRefGoogle Scholar
  73. 73.
    Medical Research Council. Combination chemotherapy with or without bevacizumab in treating patients with previously untreated stomach cancer or gastroesophageal junction cancer that can be removed by surgery [ClinicalTrials.gov identifier NCT00450203]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 2]

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Branislav Bystricky
    • 1
  • Alicia F. C. Okines
    • 1
  • David Cunningham
    • 1
  1. 1.Department of MedicineRoyal Marsden Hospital NHS TrustSutton, SurreyUK

Personalised recommendations